Genomic Health said a study of its Oncotype DX Genomic Prostate Score (GPS) test validate the test as an independent predictor of adverse pathology as a measure of tumor aggressiveness in men with localized prostate cancer. A second analysis reinforces that the test significantly increases use and persistence on active surveillance.
The company said results from 258 patients demonstrated that use of the test changed initial treatment recommendations for 23% of patients, which is consistent with previously reported studies and highlights the value of the test in guiding initial treatment decisions. Moreover, 62% of the GPS-tested patient population selected active surveillance compared to 40% of the men who did not receive the test. Of men who selected active surveillance initially, the vast majority (89%) remained on active surveillance at one year based on personalized genomic information from the GPS test.